BIOKERALTY RESEARCH INSTITUTE AIE

Their core work

Biokeralty is a Spanish research institute specializing in nanomedicine formulation, GMP-grade manufacturing scale-up, and safety/regulatory evaluation of nano-enabled medical products. Their core work involves developing nanoparticle-based drug delivery systems — magnetic nanoparticles for cancer therapy, liposomal nanocarriers for rare diseases, and transmembrane therapeutics for cystic fibrosis. They bridge the gap between lab-scale nanomedicine research and clinical-grade production, contributing manufacturing expertise and regulatory know-how to multi-partner European consortia.

What they specialise in

How they've shifted over time

Biokeralty's early H2020 work (2016–2018) was firmly rooted in hands-on nanomedicine R&D: developing magnetic nanoparticles for pancreatic cancer therapy, liposomal nanocarriers crossing the blood-brain barrier for Fabry disease, and GMP manufacturing scale-up. From 2019 onward, their focus shifted markedly toward the regulatory and safety evaluation side — assessing medical devices, building regulatory frameworks for nanomaterials, and contributing to open innovation platforms. This reflects a maturation from "making the nanoparticles" to "ensuring they are safe, compliant, and market-ready."

Biokeralty is moving downstream from nanomedicine development toward safety assessment and regulatory readiness, positioning itself as a partner for bringing nano-enabled medical products to market.

How they like to work

Biokeralty operates exclusively as a consortium partner — never as coordinator — typically joining large, well-funded research consortia (89 unique partners across 22 countries). Their consistent participant role across both RIA and IA projects suggests they contribute specialized technical capacity rather than project leadership. With nearly 90 distinct partners, they function as a broadly networked specialist rather than a hub builder, making them an accessible and experienced consortium member for new collaborations.

Biokeralty has collaborated with 89 unique partners across 22 countries, giving them one of the broader networks for an organization of their size. Their partnerships span Western and Southern Europe heavily, with reach into international cooperation beyond EU borders (evidenced by REFINE's international cooperation keyword).

What sets them apart

Biokeralty combines two capabilities that rarely sit in the same organization: hands-on nanomedicine manufacturing (GMP-grade nanoparticle and liposomal formulation) and regulatory/safety expertise for nano-enabled medical products. For consortium builders, this means one partner can contribute both the production knowledge and the regulatory navigation needed to move nanomedicines toward clinical use. Their location in Spain's Basque Country (linked to the Praxis Group) gives them access to regional biotech infrastructure while maintaining a broad European collaboration network.

Highlights from their portfolio

• NoCanTher
  Largest single grant (EUR 1.49M) — a flagship nanomedicine project scaling magnetic nanoparticle cancer therapy from lab to GMP production and Phase I clinical trial readiness.
• SAFE-N-MEDTECH
  Highest funding received (EUR 1.57M) and marks Biokeralty's strategic pivot into safety testing and lifecycle assessment of nano-enabled medical technologies.
• Smart-4-Fabry
  Rare disease focus (Fabry disease) with an innovative green GMP manufacturing approach for liposomal nanocarriers — demonstrates capability in orphan drug delivery.